Dyadic International (DYAI) Revenue Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Revenue Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.70 Bn | 192.71 Bn | 7.24 Bn | 9.53% |
| 2 | Gilead Sciences | 180.18 Bn | 177.00 Bn | 6.22 Bn | 10.18% |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 12.45% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 16.73% |
| 5 | Argenx Se | 60.60 Bn | 55.42 Bn | 1.37 Bn | 59.71% |
| 6 | Moderna | 53.81 Bn | 48.67 Bn | 52.00 Mn | 2.11% |
| 7 | Alnylam Pharmaceuticals | 33.46 Bn | 30.15 Bn | 992.69 Mn | 66.86% |
| 8 | Biogen | 31.82 Bn | 30.54 Bn | 1.96 Bn | 3.42% |
| 9 | Roivant Sciences | 29.10 Bn | 29.10 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 182.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 182.28% |
| Dec 31, 2025 | -30.81% |
| Sep 30, 2025 | -40.50% |
| Jun 30, 2025 | 150.49% |
| Mar 31, 2025 | 17.62% |
| Dec 31, 2024 | 19.06% |
| Sep 30, 2024 | 393.00% |
| Jun 30, 2024 | -53.90% |
| Mar 31, 2024 | -65.79% |
| Dec 31, 2023 | -7.69% |
| Sep 30, 2023 | -54.86% |
| Jun 30, 2023 | 27.12% |
| Mar 31, 2023 | 50.83% |
| Dec 31, 2022 | 137.39% |
| Sep 30, 2022 | 26.94% |
| Jun 30, 2022 | -29.72% |
| Mar 31, 2022 | -99.86% |
| Dec 31, 2021 | -9.43% |
| Sep 30, 2021 | 66.43% |
| Jun 30, 2021 | 78.74% |